Enrico Pesenti, DVM

Executive Director, Client Engagement

EDUCATION/TRAINING

Institution and Location	Degree & Field of Study
University of Milano, Milano, 1987-1989	Post-doctoral diploma in Hygiene and Prophylaxis of Infectious Diseases
Mario Negri Institute of Pharmacological Research, Milano, 1985-1988	Post-doctoral diploma in Pharmacological Research
University of Milano, 1979-1985	Degree in Veterinary Medicine

PERSONAL STATEMENT

After graduating in Veterinary Medicine at the University of Milan, I spent three years as researcher in Alberto Mantovani Lab at the "Mario Negri Institute of Pharmacological Research" in Milan, and then I started my career in the pharmaceutical industry, within Farmitalia-Carlo Erba, Pharmacia, Pfizer, and Nerviano Medical Sciences, acquiring a solid knowledge in cell biology, in vivo pharmacology and imaging, and a successful experience in targeted therapies development, contributing to the development of currently marketed anticancer drugs. In 2012, I was appointed CEO of Accelera Srl, a preclinical Contract Research Organization, part of the NMS Group, holding my position in the NMS Oncology organization as member of the Management Team. In 2021. I moved to Rottapharm-Biotech as Director of Translational Pharmacology, with focus on innovative projects in Immuno-Oncology and Osteoarthritis. Since October 2022, I am part of Crown Bioscience as Executive Director of Client Engagement. I am leading an international team of high-profile scientists, providing scientific support and consultancy to customers, with a drive to enhance the client experience and delivery of excellence throughout. I am co-author of more than fifty peer-reviewed publications and co-inventor of several international patent applications.

SCIENTIFIC APPOINTMENTS

2022 – present	Executive Director, Client Engagement, Crown Bioscience
2021 – 2022	Director of Translational Pharmacology, Rottapharm Biotech
2012 – 2021	CEO, Accelera
2006 – 2015	Management Team, Oncology, Nerviano Medical Sciences
2004 – 2015	Director, Pharmacology Department, Oncology, Nerviano Medical Sciences
1997 – 2004	Head of Experimental Therapy, Oncology, Pharmacia/Pfizer
1998 – 1999	Discovery Project Leader, Oncology, Pharmacia
1995 – 1997	Development Project Leader, Oncology, Pharmacia
1988 – 1995	Researcher, Oncology, Pharmacia/Farmitalia Carlo Erba

INDUSTRY ACHIEVEMENTS / HONORS

Member of the American Association of Cancer Research, since 2005

RELEVANT PUBLICATIONS

Visone R, Lozano-Juan F, Marzorati S, Rivolta MW, **Pesenti E**, Redaelli A, Sassi R, Rasponi M, Occhetta P. Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform. Toxicol Sci. 2023

Visone R, Ugolini GS, Cruz-Moreira D, Marzorati S, Piazza S, **Pesenti E**,Redaelli A, Moretti M, Occhetta P, Rasponi M. Micro-electrode channel guide (μECG) technology: an online method for continuous electrical recording in a human beating heart-on-chip. Biofabrication. 2021

Tosca EM, Rocchetti M, **Pesenti E**, Magni P. A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance. Cancer Res. 2020 Feb 15;80(4):820-831

Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, **Pesenti E**, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. J Med Chem. 2016 Apr 14;59(7):3392-408.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, **Pesenti E**, Magnaghi P, Galvani A. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016 Apr;15(4):628-39

Golay J, D'Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, Cribioli S, Albanese C, **Pesenti E**, Finazzi MC, Quaresmini G, Nagorsen D, Introna M, Rambaldi A. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. J Immunol. 2014 Nov 1;193(9):4739-47.

Valgardsdottir R, Capitanio C, Texido G, Pende D, Cantoni C, **Pesenti E**, Rambaldi A, Golay J, Introna M. Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. Exp Hematol. 2014 Dec;42(12):1013-21.

Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, **Pesenti E**, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014 Dec;8(8):1495-507

Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, **Pesenti E**, Alzani R. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, **Pesenti E**, Rizzi S, Rocchetti M, Sola F, Moll J. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16

Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, **Pesenti E**, Galvani A, Isacchi A, Colotta F, Donati D, Moll J. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res. 2010 Dec 15;70(24):10255-64.

Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, **Pesenti E**, Mercurio C, Ciomei M. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther. 2010 Aug;9(8):2243-54.

RELEVANT PUBLICATIONS

Locatelli G, Bosotti R, Ciomei M, Brasca MG, Calogero R, Mercurio C, Fiorentini F, Bertolotti M, Scacheri E, Scaburri A, Galvani A, **Pesenti E**, De Baere T, Soria JC, Lazar V, Isacchi A. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol Cancer Ther. 2010 May;9(5):1265-73

Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F, Stortini G, Scanziani E, **Pesenti E**, Alzani R. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol. 2009 Jul;24(7):879-91

Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, **Pesenti E**, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4(6):357-65.

Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, **Pesenti E**, Fancelli D, Moll J. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68

Degrassi A, Russo M, Scanziani E, Giusti A, Ceruti R, Texido G, **Pesenti E**. Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials. Prostate. 2007 Mar 1;67(4):396-404.

Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, **Pesenti E**, Terron A, Sbarbati A, Osculati F. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res. 2005 Aug 15;11(16):5827-32

Abrams TJ, Murray LJ, **Pesenti E**, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003 Oct;2(10):1011-21.

Marzola P, Farace P, Calderan L, Crescimanno C, Lunati E, Nicolato E, Benati D, Degrassi A, Terron A, Klapwijk J, **Pesenti E**, Sbarbati A, Osculati F. In vivo mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (Kps) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure. Int J Cancer. 2003 Apr 20;104(4):462-8